Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Leahey

Cardiovascular Disease Baytown, TX Medical Doctor

NPI 1770584690 CMS profile 34711

4201 Garth Rd, 100, Baytown, TX 77521

Open in the dashboard

General payments

$81,268

828 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Leahey of Baytown, TX is reported in the CMS Open Payments database as having received $81,268 across 828 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,134 52
2024 General $2,052 108
2023 General $2,707 122
2022 General $2,908 123
2021 General $2,916 135
2020 General $2,400 108
2019 General $67,152 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Leahey
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Edward Leahey were reported at $1,134. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Edward Leahey Cardiovascular Disease median Middle half National median
2019 $67,152 $450 $127–$1,392 $163
2020 $2,400 $242 $77–$751 $114
2021 $2,916 $335 $101–$1,037 $132
2022 $2,908 $395 $121–$1,211 $149
2023 $2,707 $443 $136–$1,283 $160
2024 $2,052 $450 $136–$1,323 $164
2025 $1,134 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $62,541 1 payment
  2. Abbott Laboratories $6,203 148 payments
  3. Amgen Inc. $1,275 71 payments
  4. Novartis Pharmaceuticals Corporation $1,150 78 payments
  5. Shockwave Medical, Inc $934 35 payments
  6. Pfizer Inc. $918 54 payments
  7. Amarin Pharma Inc. $829 53 payments
  8. Janssen Pharmaceuticals, Inc $807 44 payments
  9. Merck Sharp & Dohme Corporation $746 39 payments
  10. Boston Scientific Corporation $650 29 payments
  11. Other $5,214 276 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $62,541 1 payment
  2. Food and Beverage $17,374 806 payments
  3. Travel and Lodging $1,227 5 payments
  4. Education $126 16 payments
Products named General payments · program years 2019–2025
  1. VenaSeal $62,541 1 payment
  2. Xience V coronary stent system $1,087 3 payments
  3. Repatha $1,080 60 payments
  4. ELIQUIS $859 50 payments
  5. VERQUVO $857 44 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $853 31 payments
  7. XARELTO $807 44 payments
  8. LEQVIO $686 42 payments
  9. LifeVest $617 38 payments
  10. Vascepa $607 33 payments
  11. Other $13,665 596 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

11,919

Median for Cardiology: 2,533

Drug cost

$1,941,443

Median for Cardiology: $485,213

Branded share of claims

33.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 681 $691,329
Repatha Sureclick Evolocumab Brand 336 $380,105
Entresto Sacubitril/Valsartan Brand 234 $273,582
Xarelto Rivaroxaban Brand 180 $180,664
Brilinta Ticagrelor Brand 58 $60,530
Praluent Pen Alirocumab Brand 62 $55,928
Multaq Dronedarone Hcl Brand 26 $43,272
Vascepa Icosapent Ethyl Brand 55 $32,715
Nexlizet Bempedoic Acid/Ezetimibe Brand 40 $26,013
Repatha Syringe Evolocumab Brand 30 $21,999

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$404,957

Of which drugs: $5,097

Medicare patients

554

Average age 76

Services billed

6,979

284 women, 270 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 49%
Diabetes 42%
Atrial fibrillation 36%
Chronic kidney disease 35%
Heart failure 31%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 198 789 $5,097

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $254
$254 180 —
Repatha
  • Amgen Inc. $159
$159 366 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $127
$127 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $111
$111 — —
ELIQUIS
  • PFIZER INC. $79
$79 681 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

828 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record